AMED

NEC selected by AMED for design of a universal vaccine that is effective against influenza virus strains

Retrieved on: 
Thursday, September 14, 2023

During this research project, NEC will utilize cutting-edge AI technologies in order to identify immunogenic regions that are effective against a wide range of influenza virus strains and to design a universal vaccine.

Key Points: 
  • During this research project, NEC will utilize cutting-edge AI technologies in order to identify immunogenic regions that are effective against a wide range of influenza virus strains and to design a universal vaccine.
  • Research on universal vaccines that are broadly protective against mutating viruses are being conducted around the world in preparation for future pandemics.
  • However, it is likely to take a considerable amount of time for universal vaccines to be put to practical use.
  • "We are pleased that our proposal has been selected by SCARDA for the development of universal vaccine design technology through industry-government-academia collaboration.

Mitsubishi Electric, Okayama University, and Osaka University Develop Magnetic Particle Imaging Device Capable of Producing Images of Human Brain

Retrieved on: 
Thursday, September 7, 2023

Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED).

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED).
  • The device operates at low frequencies of 1 kHz or less, a world-first, allowing the use of a significantly smaller power supply unit.
  • The utilization of this device to image magnetic particles that bind to amyloid-β, the causative agent of Alzheimer's, will allow the accumulation and distribution of amyloid-β to be quantified.
  • The aim is to allow imaging-based assessments of the likelihood of Alzheimer's developing prior to the onset of the disease.

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

Retrieved on: 
Thursday, July 6, 2023

By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.

Key Points: 
  • By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
  • Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT.
  • Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
  • From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022.

George Clinical and EPS Collaborate on Important HR+/HER2- Breast Cancer Study in Asia Pacific

Retrieved on: 
Tuesday, June 27, 2023

In 2016, among all the Clinical Research Core Hospitals in Japan, NCCH was selected by AMED (Japan Agency for Medical Research and Development) as one of the Global Clinical Trials Core Centers, focused on the reinforcement of facilitating international clinical trials in Japan between 2016-2018. This study is their first global investigator-initiated registration-directed trial (IIRDT) -- an important step toward the pursuit of the development of treatments and new drugs for the Asian population.

Key Points: 
  • In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region.
  • Since September 2019, EPS and George Clinical have been involved in a major study for the National Cancer Center Hospital, Japan (NCCH) on the clinical usefulness of a combination therapy in patients of any menopausal status with advanced or metastatic HR+/HER2- breast cancer.
  • George Clinical is entirely responsible for study execution in Singapore and Taiwan with specific duties including full study conduct, regulatory, safety reporting and site monitoring.
  • George Clinical's strong expertise in regulatory, site knowledge and oncology expertise in the Asia Pacific region add value to the EPS strengths in Japan.

Amedisys Announces Receipt of Unsolicited Proposal From Optum

Retrieved on: 
Monday, June 5, 2023

BATON ROUGE, La., June 05, 2023 (GLOBE NEWSWIRE) --  Amedisys, Inc. (“Amedisys” or the “Company”) (NASDAQ: AMED) today announced that on May 26, 2023, the Company received an unsolicited proposal from Optum, a diversified health services company, to acquire all of the outstanding shares of Amedisys’ common stock in an all-cash transaction for $100 per share.

Key Points: 
  • As announced on May 3, 2023, Amedisys entered into a merger agreement with Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), under which Amedisys and Option Care Health would combine in an all-stock transaction.
  • On May 27, 2023, the Board determined that the unsolicited proposal received from Optum could reasonably be expected to result in an “Amedisys Superior Proposal” as defined in Amedisys’ merger agreement with Option Care Health.
  • As permitted by the terms of Amedisys’ merger agreement with Option Care Health, Amedisys entered into a confidentiality agreement with Optum on May 30, 2023, and is currently engaging in exploratory discussions with Optum with respect to Optum’s proposal.
  • Amedisys remains bound by the terms of the merger agreement with Option Care Health, and Amedisys’ Board has not determined that Optum’s proposal constitutes a Superior Proposal as defined in the merger agreement with Option Care Health.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MMP, CTIC, HMPT, AMED

Retrieved on: 
Wednesday, May 17, 2023

Under the terms of the agreement, MMP shareholders are expected to receive $25.00 in cash and 0.6670 shares of ONEOK per share they own.

Key Points: 
  • Under the terms of the agreement, MMP shareholders are expected to receive $25.00 in cash and 0.6670 shares of ONEOK per share they own.
  • CTI Biopharma Corp, Inc. (NASDAQ: CTIC ), relating to its proposed sale to Swedish Orphan Biovitrum AB.
  • Amedisys, Inc. (NASDAQ: AMED ), relating to its proposed merger with Option Care Health, Inc.
  • Under the terms of the agreement, AMED shareholders are expected to receive 3.0213 share of Option Care per share they own.

Saisei Ventures is Selected as a Certified VC Fund by AMED to Catalyze the Japanese Drug Development Ecosystem

Retrieved on: 
Wednesday, May 17, 2023

Through this initiative, AMED subsidizes the development of therapeutic assets by providing additional grant funding to ventures that have received investments from certified VC firms.

Key Points: 
  • Through this initiative, AMED subsidizes the development of therapeutic assets by providing additional grant funding to ventures that have received investments from certified VC firms.
  • Under the Strengthening Program for Pharmaceutical Startup Ecosystem initiative, AMED certifies VC firms and fund managers that have a demonstrated track record of therapeutic investment and can provide specialized hands-on commercialization support for preclinical to clinical stage drug development.
  • “We are pleased to be selected as a certified VC by AMED, enabling us to bolster our investments by leveraging these development funds,” says Jonathan Yeh, Managing Partner at Saisei Ventures.
  • In addition to Saisei Ventures, the other selected firms include:
    JIC Venture Growth Investments Co., Ltd.
    Osaka University Venture Capital Co., Ltd.

Lifshitz Law PLLC Announces Investigations of CTIC, ARNC, AMED, and OPCH

Retrieved on: 
Sunday, May 14, 2023

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CTIC to Swedish Orphan Biovitrum AB for $9.10 per share in cash.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CTIC to Swedish Orphan Biovitrum AB for $9.10 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ARNC to Apollo Global Management, Inc. for $30.00 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of OPCH and Amedisys Inc.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Retrieved on: 
Friday, November 4, 2022

The European Commission has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

Key Points: 
  • The European Commission has approved Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
  • Beyfortus has been developed to offer newborns and infants direct RSV protection via an antibody to help prevent LRTI caused by RSV.
  • Healthy preterm infants of 2935 weeks gestation were randomized (2:1) to receive a single 50mg intramuscular injection of Beyfortus or placebo.
  • Between November 2016 and December 2017, 1,453 infants were randomized (Beyfortus, n=969; placebo, n=484) at the RSV season start.

FDA Accepts NMP's Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis

Retrieved on: 
Tuesday, October 25, 2022

TOKYO, Oct. 25, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, is pleased to announce that the U.S. Food and Drug Administration (FDA) has recently accepted NMP's Investigational New Drug (IND) application to initiate a first-in-human phase I clinical study of "NMK89 (development code)," which is an imaging agent currently developed for cancer diagnostic use in cancer theranostics (a fusion of therapeutics and diagnostics) (*1). The clinical study can now be started.

Key Points: 
  • NMK89 is an RI (*2)-labeled humanized anti-MUC5AC (*3) antibody to which zirconium-89, a diagnostic radionuclide, is labeled and has been investigated in non-clinical studies conducted by NMP and Sumitomo Pharma Co., Ltd. as an imaging agent for the diagnosis of MUC5AC-expressing cancer.
  • It has been reported that MUC5AC is highly expressed in pancreatic cancer, liver cancer, colon cancer, gastric cancer, and lung cancer, among others.
  • Non-clinical studies have confirmed that NMK89 accumulates in tumors transplanted with cell lines expressing MUC5AC.
  • Nihon Medi-Physics is engaging in ensuring stable supply and research and development of new products as a leading manufacturer of radiopharmaceuticals in Japan.